BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer
Phase Ib / II study to determine the Maximum Tolerated Dose and Recommended Phase II Dose, and to evaluate the safety and antitumour activity, of BI 836845 and everolimus in combination with exemestane in women with HR+/HER2- advanced breast cancer
Neoplasms
DRUG: Everolimus|DRUG: Everolimus|DRUG: Everolimus|DRUG: Exemestane|DRUG: BI 836845|DRUG: BI 836845|DRUG: Exemestane|DRUG: Exemestane
Progression-free survival (PFS), up to 11 months|Occurrence of Dose Limiting Toxicity (DLT) - phase I part, up to 28 days|Maximum Tolerated Dose (MTD) - phase I part, up to 15 months
Objective response (OR), defined as complete response (CR) or partial response (PR) (CR + PR), up to 11 months|Time to progression (TTP), defined as the duration of time from the date of randomization until the date of the first objective tumor progression, up to 11 months|Disease control (DC), defined as best overall response of complete response (CR) or partial response (PR), or stable disease (SD) >=24 weeks, or Non-CR/Non-PD for >=24 weeks (CR + PR + SD24w + Non-CR/Non-PD24w), up to 11 months|Time to objective response, defined as the time from randomisation until first documented CR or PR, up to 11 months|Duration of objective response, defined as the time from first documented CR or PR until the earliest of disease progression or death among patients with OR, up to 11 months|Duration of disease control, defined as the time from randomisation until the earliest of disease progression or death, among patients with disease control, up to 11 months
Phase Ib / II study to determine the Maximum Tolerated Dose and Recommended Phase II Dose, and to evaluate the safety and antitumour activity, of BI 836845 and everolimus in combination with exemestane in women with HR+/HER2- advanced breast cancer